Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07233239 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
A Phase 1 study of Focal Seizures, sponsored by Jazz Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT07233239 is a Phase 1 study of Focal Seizures that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 100 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT07233239, a Phase 1 study of Focal Seizures, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).
Conditions Studied
Interventions
- DRUG CBD-OS
Study Locations (20)
Georgia
- Emory University - Atlanta
- Savannah Neurology Specialists - Savannah
Michigan
- Wayne State University - Detroit
- Corewell Health - Grand Rapids
New Jersey
- Hackensack Meridian Neuroscience Institute at JFK University Medical Center - Edison
- Saint Peter's University Hospital - New Brunswick
North Carolina
- Onsite Clinical Solutions - Charlotte
- Velocity Clinical Research at Raleigh Neurology - Raleigh
Ohio
- Cincinnati Children's Hospital - Cincinnati
- University of Cincinnati, Gardner Neuroscience Institute - Cincinnati
Arizona
- Banner University Medical Center-Phoenix - Phoenix
California
- UC San Diego - La Jolla
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-11-26 |
| Est. Completion | 2027-11-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07233239
The ClinicalTrials.gov registry entry for NCT07233239 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Focal Seizures appearing as the primary indexed condition, and to 1 intervention - of which CBD-OS is the first listed.
NCT07233239 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Georgia, Michigan, New Jersey.
Frequently Asked Questions
What is clinical trial NCT07233239 about?
NCT07233239 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures". Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participant...
What is the current status of trial NCT07233239?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-11-26. Estimated completion is 2027-11-29.
What conditions does trial NCT07233239 study?
This clinical trial studies the following conditions: Focal Seizures.
What interventions are being tested in trial NCT07233239?
The interventions under investigation include: CBD-OS (DRUG).
Who is sponsoring clinical trial NCT07233239?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07233239 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.